Ronald J Oudiz MD
Adult Congenital Heart Disease
Director, Liu Center for Pulmonary Hypertension
Join to View Full Profile
21840 Normandie AveSte. 700Torrance, CA 90502
Phone+1 310-222-5101
Fax+1 310-320-5463
Are you Dr. Oudiz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ronald Oudiz, MD is a cardiologist in Torrance, California. He is currently licensed to practice medicine in California. He is a Director at Liu Center for Pulmonary Hypertension.
Education & Training
Los Angeles County-Harbor-UCLA Medical CenterFellowship, Cardiovascular Disease, 1992 - 1995
University of California (San Diego) Medical CenterInternship, Internal Medicine, 1989 - 1990
Keck School of Medicine of the University of Southern CaliforniaClass of 1989
Certifications & Licensure
CA State Medical License 1990 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- 1 citationsRandomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.Marius M Hoeper, Ralf Ewert, Pavel Jansa, Yuriy Sirenko, Andris Skride
Circulation. 2024-06-18 - 1 citationsThe ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells.Michael I Lewis, Shelley Shapiro, Ronald J Oudiz, Mamoo Nakamura, Dael Geft
Ebiomedicine. 2024-02-01 - 2 citationsParenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil.Chad E Miller, Veronica Franco, Jimmy S Smith, Vijay Balasubramanian, John Kingrey
Respiratory Medicine. 2023-11-01
Press Mentions
I’m Aware That I’m Rare: Alejandra HernandezApril 23rd, 2019
ZappRx Implements Specialty Medication Prescribing Platform at 2 Pulmonary Medical CentersJuly 25th, 2017
Reata Announces Initial Phase 2 Pulmonary Arterial Hypertension Data for Bardoxolone Methyl and Planned Initiation of Phase 3 StudyOctober 27th, 2015- Join now to see all
